News | August 13, 2025
Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
_256_384.jpg)
Marksans Pharma gets USFDA nod for acid reflux drug
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
IOLCP has reported total income of Rs. 559.06 crores during the period ended June 30, 2025
The submission is supported by positive results from the Phase 3 AMPLIFY trial
Mehta brings strong leadership experience in biopharmaceuticals, life science research, and diagnostics
The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters
His career spans notable tenures at Syngene International Limited, Cipla, Nestlé, and Bharat Petroleum Corporation Limited
Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Subscribe To Our Newsletter & Stay Updated
